Search results
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 5 days agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
Germany’s Merck Bets on AI Drug-Design Partnerships, Rules Out Acquisitions – Interview
The Wall Street Journal· 11 hours agoMerck—known as EMD Group in the U.S.— is betting on artificial-intelligence partnerships to develop...
Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.
The Wall Street Journal· 5 days agoMore patients can fend off the disease for months or years with targeted or immune-boosting drugs,...
ASCO 2024: What's New in Breast Cancer Research?
Medscape· 2 days agoDrs Alexandra Thomas and Virginia Kaklamani discuss highlights in breast cancer research from the ASCO 2024 Annual Meeting.
Women denied ‘wonder drug’ that could double terminal breast cancer life expectancy
Daily Telegraph· 4 days agoWomen with HER2-low or ultra-low breast cancer who took Enhertu lived without their cancer growing...
Democrats ramp up patent fight with drug industry in bid to lower prices
Anchorage Daily News· 3 hours agoDemocrats have hit on a new tactic in their long battle with drug companies: challenge patents that...
AstraZeneca PLC ADR TradeGate Stock Price Today | NASDAQ AZNPy Live Ticker - Investing.com
Investing.com· 2 days agoRisk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for ...
Astra’s Enhertu delays breast cancer in patients with low HER2 levels
WSAU Wausau· 5 days agoBy Deena Beasley (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to...
'Outstanding' Results for Osimertinib: Stage III EGFR+ NSCLC
Medscape· 4 days agoResults from the LAURA trial will change practice once its label gets expanded, experts said at the...
Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
Zacks via Yahoo Finance· 1 day agoEmpaveli recorded sales of $25.6 million in the reported quarter, up 25.5% from the year-ago...